IMUNON rises as ovarian cancer drug prolongs survival in mid-stage study
Shares of biotech firm IMUNON IMNN.O rise 6.8% to $3.10 premarket
Co says its experimental drug IMNN-001 helped patients with advanced ovarian cancer, a deadly cancer that is often diagnosed late and frequently returns after treatment
Final data from a mid‑stage study shows median overall survival of 45.1 months with IMNN-001 plus chemotherapy vs 30.4 months with chemotherapy alone, co says
Says survival rose to 65.6 months when IMNN-001 was used with chemo and PARP inhibitors, drugs that stop cancer cells from repairing DNA
IMNN-001 is given directly into the abdomen to stimulate the immune system and showed a favourable safety profile, co says
Says enrolment in a late‑stage trial is ahead of schedule, targeting about 500 patients
Shares down ~69% in 2025
